132 related articles for article (PubMed ID: 37946299)
1. Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA.
Heger JM; Mattlener J; Schneider J; Gödel P; Sieg N; Ullrich F; Lewis R; Bucaciuc-Mracica T; Schwarz RF; Rueß D; Ruge MI; Montesinos-Rongen M; Deckert M; Blau T; Kutsch N; Balke-Want H; Weiss J; Becker K; Reinhardt HC; Hallek M; Borchmann P; von Tresckow B; Borchmann S
Blood; 2024 Feb; 143(6):522-534. PubMed ID: 37946299
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.
Mutter JA; Alig SK; Esfahani MS; Lauer EM; Mitschke J; Kurtz DM; Kühn J; Bleul S; Olsen M; Liu CL; Jin MC; Macaulay CW; Neidert N; Volk T; Eisenblaetter M; Rauer S; Heiland DH; Finke J; Duyster J; Wehrle J; Prinz M; Illerhaus G; Reinacher PC; Schorb E; Diehn M; Alizadeh AA; Scherer F
J Clin Oncol; 2023 Mar; 41(9):1684-1694. PubMed ID: 36542815
[TBL] [Abstract][Full Text] [Related]
3. Clinical applications of circulating tumor DNA in central nervous system lymphoma.
Foerster AK; Lauer EM; Scherer F
Semin Hematol; 2023 Jul; 60(3):150-156. PubMed ID: 37442670
[TBL] [Abstract][Full Text] [Related]
4. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas.
Bobillo S; Crespo M; Escudero L; Mayor R; Raheja P; Carpio C; Rubio-Perez C; Tazón-Vega B; Palacio C; Carabia J; Jiménez I; Nieto JC; Montoro J; Martínez-Ricarte F; Castellvi J; Simó M; Puigdefàbregas L; Abrisqueta P; Bosch F; Seoane J
Haematologica; 2021 Feb; 106(2):513-521. PubMed ID: 32079701
[TBL] [Abstract][Full Text] [Related]
5. Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas.
Lauer EM; Riegler E; Mutter JA; Alig SK; Bleul S; Kuehn J; Ranganathan L; Klingler C; Demerath T; Würtemberger U; Rau A; Weiß J; Eisenblaetter M; Bamberg F; Prinz M; Finke J; Duyster J; Illerhaus G; Diehn M; Alizadeh AA; Schorb E; Reinacher PC; Scherer F
Neuro Oncol; 2024 Feb; 26(2):374-386. PubMed ID: 37713267
[TBL] [Abstract][Full Text] [Related]
6. Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases.
Iriyama C; Murate K; Iba S; Okamoto A; Goto N; Yamamoto H; Kato T; Mihara K; Miyama T; Hattori K; Kajiya R; Okamoto M; Mizutani Y; Yamada S; Tsukamoto T; Hirose Y; Mutoh T; Watanabe H; Tomita A
Cancer Med; 2023 Aug; 12(16):16972-16984. PubMed ID: 37501501
[TBL] [Abstract][Full Text] [Related]
7. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma.
Strehlow F; Bauer S; Martus P; Weller M; Roth P; Schlegel U; Seidel S; Scheibenbogen C; Korfel A; Kreher S
J Neurooncol; 2016 Aug; 129(1):165-71. PubMed ID: 27294357
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.
Li M; Mi L; Wang C; Wang X; Zhu J; Qi F; Yu H; Ye Y; Wang D; Cao J; Hu D; Yang Q; Zhao D; Ma T; Song Y; Zhu J
BMC Med; 2022 Oct; 20(1):369. PubMed ID: 36280874
[TBL] [Abstract][Full Text] [Related]
10. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
[TBL] [Abstract][Full Text] [Related]
11. Current Role and Future Potential of CSF ctDNA for the Diagnosis and Clinical Management of Pediatric Central Nervous System Tumors.
Miller AM; Karajannis MA
J Natl Compr Canc Netw; 2022 Dec; 20(12):1363-1369. PubMed ID: 36509077
[TBL] [Abstract][Full Text] [Related]
12. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
[TBL] [Abstract][Full Text] [Related]
13. Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma.
Yoon SE; Kim YJ; Shim JH; Park D; Cho J; Ko YH; Park WY; Mun YC; Lee KE; Cho D; Kim WS; Kim SJ
Cancer Res Treat; 2022 Apr; 54(2):597-612. PubMed ID: 34325497
[TBL] [Abstract][Full Text] [Related]
14. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
[TBL] [Abstract][Full Text] [Related]
16. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
[TBL] [Abstract][Full Text] [Related]
17. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
[TBL] [Abstract][Full Text] [Related]
18. Central Nervous System Lymphoma: Approach to Diagnosis and Treatment.
Correia CE; Schaff LR; Grommes C
Cancer J; 2020; 26(3):241-252. PubMed ID: 32496457
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of serum and cerebrospinal fluid MMP-9, CCL2 and sVCAM-1 in leukemia CNS metastasis.
Si MY; Fan ZC; Li YZ; Chang XL; Xie QD; Jiao XY
J Neurooncol; 2015 Apr; 122(2):229-44. PubMed ID: 25630624
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
